A tale of two stakeholder groups in regulating healthcare AI
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA combines in-depth industry knowledge and cutting-edge analytics to evaluate issues being litigated and debated in the healthcare sector. Our industry knowledge enables us to explain, for example, the nuances of provider reimbursement or the patient incentives created by high deductible health insurance plans, and our economic, statistical, accounting, investigative, and finance skills—as well as our familiarity with key healthcare datasets—equips CRA to provide rigorous, defensible analyses tailored to the specific facts of a litigation or regulatory dispute.
Our experts have broad and deep experience in the healthcare sector including hospitals, physician practices, health insurance and health benefit plans, ACOs, PBMs, wholesalers, pharmacies, pharmaceuticals and biologicals, medical devices, clinical laboratories, dialysis facilities, ambulance transport, nursing homes, and home healthcare.
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...
In the United States, drug shortages have become a persistent public health issue, negatively impacting patient care and outcomes. In the last decade, the...
CRA is a proud sponsor of the event covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes...
Peter Boberg, Sandra Chan, Matt List and Sean May present the Health Care & Pharmaceutical Committee’s quarterly update, summarizing the most important...